Spots Global Cancer Trial Database for Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

Official Title: Twice-daily Radiotherapy by Simultaneous Integrated Boosting Technique Versus Twice-daily Standard Radiotherapy for Patients With Limited-stage Small Cell Lung Cancer: a Multicenter, Randomized, Controlled, Phase III Study

Study ID: NCT03214003

Conditions

Small Cell Lung Cancer Limited Stage

Radiotherapy

Interventions

SIB

Standard

Study Description

Brief Summary: This trial is a multicenter, perspective, non-blinded, randomized controlled phase 3 trial. In order to establish whether the SIB technique can improve the results of twice-daily chemo-RT for patients with LS-SCLC, the investigators will primarily compare survival of patients treated with standard chemotherapy (cisplatin and etoposide) and either SIB twice-daily RT or standard dose twice-daily RT.

Detailed Description: Three hundred and twenty-six patients with a histological or cytological proven diagnosis of SCLC will be recruited from 35 centers in 14 areas including provinces, municipalities and autonomous region, from May 2017 to May 2020.